Cytek Biosciences, Inc. CTKB Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytek Biosciences, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytek Biosciences, Inc.'s change in accrued liabilities?
- Cytek Biosciences, Inc. (CTKB) reported change in accrued liabilities of -$3.89M in Q1 2026.
- How has Cytek Biosciences, Inc.'s change in accrued liabilities changed year-over-year?
- Cytek Biosciences, Inc.'s change in accrued liabilities decreased by 83.4% year-over-year, from -$2.12M to -$3.89M.
- What is the long-term trend for Cytek Biosciences, Inc.'s change in accrued liabilities?
- Over 2 years (2021 to 2025), Cytek Biosciences, Inc.'s change in accrued liabilities has grown at a -39.9% compound annual growth rate (CAGR), from $10.98M to $3.97M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.